Mexia tablets are used for mild to severe Alzheimer's disease.
Composition
Active ingredient: memantine;
1 film-coated tablet contains 10 mg or 20 mg of memantine hydrochloride;
Excipients:
10 mg tablets: microcrystalline cellulose, lactose DC (contains lactose, povidone), colloidal silicon dioxide, talc, magnesium stearate, Opadry Y-January 7000 White coating (contains hypromellose, titanium dioxide (E 171), polyethylene glycol); 20 mg tablets: microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, Opadry Pink 20 A34056 coating (contains hypromellose, hydroxypropylcellulose, talc, titanium dioxide (E 171), red iron oxide (E172), black iron oxide (E172)).
Contraindication
Hypersensitivity to the active substance or to any component of the drug.
Method of application
Treatment should be initiated and continued under the supervision of a physician. Therapy should only be initiated with a caregiver who will regularly monitor the patient's medication intake.
The tablets should be taken once a day at the same time each day. The tablets can be taken with or without food.
Application features
Pregnant women
The drug should not be used during pregnancy, except in cases of clear and obvious necessity.
Children
The drug should not be used in children due to insufficient data on safety and efficacy.
Drivers
Moderate to severe Alzheimer's disease usually leads to impaired driving and impaired ability to operate machinery. Also, memantine has a minor to moderate effect on the speed of human reactions, so outpatients should be warned about the need to exercise special caution when driving vehicles or operating machinery.
Overdose
Experience is limited.
Relatively large overdoses (200 mg and 105 mg over 3 days, respectively) were either associated with symptoms of fatigue, weakness and/or diarrhea, or were asymptomatic. Overdoses up to 140 mg or an unknown dose were associated with symptoms of central nervous system disorders (confusion, lethargy, drowsiness, dizziness, agitation, aggression, hallucinations, gait disturbance) and/or gastrointestinal disorders (vomiting and diarrhea). After taking 2000 mg of memantine, a patient developed coma for 10 days, later - diplopia and agitation. After symptomatic treatment and plasmapheresis, the patient recovered without sequelae.
Treatment is symptomatic, there is no specific antidote. Standard clinical procedures should be used to remove the active substance from the body, such as gastric lavage, administration of activated charcoal, methods of acidifying the urine reaction, forced diuresis. In case of excessive general stimulation of the central nervous system, symptomatic treatment measures should be used with caution.
Side effects
On the part of the immune system: often - hypersensitivity. On the part of the psyche: often - drowsiness; infrequently - confusion, hallucinations; not specified - psychotic reactions. On the part of the nervous system: often - dizziness, balance disorders; infrequently - gait disorders; very rarely - convulsions. On the part of the heart: infrequently - heart failure. On the part of the blood vessels: often - arterial hypertension; infrequently - venous thrombosis / thromboembolism. On the part of the respiratory system: often - shortness of breath. On the part of the gastrointestinal tract: often - constipation; infrequently - vomiting; not specified - pancreatitis. On the part of the liver and biliary tract: often - increased liver function tests; not specified - hepatitis.
Interaction
The concomitant use of memantine and amantadine should be avoided due to the risk of pharmacotoxic psychosis. Both compounds are chemically related NMDA antagonists. The same may apply to ketamine and dextromethorphan.
There is evidence of a risk of psychosis when memantine and phenytoin are used together.
Storage conditions
Store at a temperature not exceeding 25 °C in the original packaging.
Keep out of reach of children.
Shelf life - 3 years.
